Eisai expands UK base
March 21, 2012Sales and Marketing EMEA, Eisai, Hatfield, expansion
Eisai is expanding its UK headquarters to support the company’s growing European, Middle Eastern and African business. The expansion will …
NICE launches new guidance app
March 20, 2012Medical Communications, Sales and Marketing Android, Apple, NICE, app, digital, guidance
NICE has launched a new app that allows mobile access to all of NICE’s recommendations and advice of the past …
Merck ends development on atrial fibrillation pill
March 20, 2012Research and Development, Sales and Marketing Cardiome, Merck, atrial fibrillation
Merck will no longer help its partner Cardiome develop an oral formulation of the atrial fibrillation drug vernakalant. The pill …
UCB signs £3.6m research deal with Oxford University
March 20, 2012Research and Development, Sales and Marketing Oxford University, UCB, collaboration, research
UCB Pharma and Oxford University have signed an R&D collaboration agreement covering immunology and neurology. The idea is to pool …
NIHR appoints Simon Denegri as national director for public participation and engagement in research
March 20, 2012Sales and Marketing INVOLVE, NHS, NIHR, Simon Denegri
The National Institute for Health Research (NIHR) has appointed Simon Denegri as its new national director for public participation and …
AstraZeneca pulls depression drug, takes $50m hit
March 20, 2012Research and Development, Sales and Marketing AstraZeneca, R&D, depression, failure, pipeline
AstraZeneca and partner Targacept will not file their depression drug TC-5214 for regulatory review. The decision comes after disappointing Phase …
Health Bill clears final Lords hurdle
March 20, 2012Sales and Marketing Health and Social Care Bill, Lords, NHS, debate, government
The Health and Social Care Bill has passed through the House of Lords, meaning it is on the verge of …
EMA completes review of Ben Venue-made drugs
March 19, 2012Manufacturing and Production Ben Venue, EMA, cancer drugs, production
The European Medicines Agency has recommended that manufacturing of two cancer medicines be transferred from Ben Venue Laboratories plant in …
AstraZeneca touting for business at partnering conference
March 19, 2012Research and Development, Sales and Marketing AstraZeneca, Bio-Europe, R&D, partnering
AstraZeneca is marketing itself as a key partner for drug development deals, ahead of a European partnering conference. The Bio-Europe …
Ranbaxy sets sights on North African pharma market
March 19, 2012Manufacturing and Production
Indian drugmaker Ranbaxy has opened a new manufacturing facility in Morocco that will help spearhead an expansion of its business …
Pharma manufacturing news in brief
March 19, 2012Manufacturing and Production Recipharm, manufacturing, production
Sweden’s Recipharm has been contracted by ViroPharma to carry out commercial-scale production of Plenadren (hydrocortisone modified release tablet), developed …
Trajenta article lands Boehringer in hot water
March 19, 2012Sales and Marketing ABPI Code, PMCPA, Trajenta, breach, diabetes
Boehringer Ingelheim has been publicly reprimanded for multiple breaches of the ABPI Code of Practice. In total the manufacturer fell …
GMC guidance on off-label drug use delayed
March 19, 2012Sales and Marketing GMC, Lucentis, avastin, off label, off-label, prescribing
The General Medical Council has delayed the release of new guidance for off-label prescribing. The doctors’ regulator was expected to …
arGEN-X appoints Alain Thibault as its new chief medical officer
March 19, 2012Sales and Marketing Alain Thibault, Regeneron, arGEN-X
arGEN-X, a biopharma firm focused on the discovery and development of human monoclonal antibodies, has appointed Alain Thibault as the …
Novartis signs experimental eye drug deal
March 19, 2012Research and Development, Sales and Marketing Novartis, ThromboGenics, vitreomacular adhesion
Novartis will develop an experimental eye drug with ThromboGenics in a pact worth nearly $500 million. The deal has been …
NICE recommends Incivo for hepatitis C
March 16, 2012Sales and Marketing Incivo, Janssen, NICE, Victrelis, telaprevir
NICE is recommending Janssen’s hepatitis C pill Incivo for funding on the NHS in England. The drug has bypassed the …
Meetings, bloody meetings
March 16, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Les Rose, Meetings, clinical trials
I read recently that less than 2% of NHS Trust board meeting agenda items require decisions. What happens during the …
GSK sells off OTC products
March 16, 2012Sales and Marketing GSK, OTC, Omega Pharma, Zantac
GlaxoSmithKline has shed more of its non-core consumer health OTC products in a £391 million sale, including a German manufacturing …
NICE U-turn sees Gilenya MS pill recommended
March 16, 2012Sales and Marketing MS, NICE, UK, fingolimod, gilenya
NICE has changed its mind on Novartis’ multiple sclerosis pill Gilenya, and is now recommending the drug in a subgroup …
Updated set of mandatory Article 57(2) requirements for marketing authorisation holders
March 15, 2012Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Wainwright Associates; EMA; Pharmacovigilance; PV
An updated set of mandatory requirements for Marketing Authorisation Holders (MAH) to comply with Article 57(2) of the forthcoming new …
Latest content
Five Facts about NHS and primary care
AI in pharma: From lab development to patient impact
